Evidence map›Paper›PMID 42040931›Full record

ArticleResearch square2026

Multiomics Profiling Supports Cathepsin B as a Protective Factor in Cerebral Small Vessel Disease.

Cyprien Rivier, Sebastian Diaz-Perez, Gael Bories, Shufan Huo, Santiago Clocchiatti-Tuozzo, Adam de Havenon, Stephanie Debette, Kevin Sheth, Lauren Sansing, Guido Falcone

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cyprien RivierYale School of Medicine.ORCID 0000-0002-1148-1829
Sebastian Diaz-PerezYale.
Gael BoriesYale.
Shufan HuoYale School of Medicine.
Santiago Clocchiatti-TuozzoYale.
Adam de HavenonYale.
Stephanie DebetteUniversity of Bordeaux.ORCID 0000-0001-8675-7968
Kevin ShethYale University.ORCID 0000-0003-2003-5473
Lauren SansingYale University.
Guido FalconeYale School of Medicine.ORCID 0000-0002-6407-0302

Funding

Yale Study Support Suite (YES3): Dashboard and Web Portal Software Supporting Research Workflow through integrated, customizable REDCap External ModulesP30AG021342 · NIA · YALE UNIVERSITY · PI Terri R. Fried · 2002 to 2026
$37.9M
Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE)U01NS106513 · NINDS · YALE UNIVERSITY · PI Hooman Kamel, Kevin Navin Sheth · 2019 to 2026
$20.6M
Yale Training Program in Geriatric Clinical Epidemiology and Aging-Related ResearchT32AG019134 · NIA · YALE UNIVERSITY · PI Terri R. Fried · 2001 to 2026
$7.5M
CTP to predict Response to recanalization in Ischemic Stroke Project (CRISP)R01NS075209 · NINDS · STANFORD UNIVERSITY · PI LANSBERG, MAARTEN G · 2011 to 2023
$6.0M
Southern New England Partnership In Stroke Research, Innovation and Treatment (SPIRIT)U24NS107215 · NINDS · YALE UNIVERSITY · PI MARK Jay ALBERTS, Karen L Furie · 2018 to 2026
$3.0M
REACH-EpiVCIDRF1NS139183 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI ANDERSON, CHRISTOPHER DAVID, ROSAND, JONATHAN · 2024 to 2024
$2.4M
Blood Pressure Variability and Ischemic Stroke Outcome (BP-VISO)R01NS130189 · NINDS · YALE UNIVERSITY · PI Adam H. de Havenon · 2023 to 2026
$2.0M
CAPTIVA-MRIUG3NS130228 · NINDS · YALE UNIVERSITY · PI AMIN-HANJANI, SEPIDEH, CHATTERJEE, ARINDAM R. · 2023 to 2023
$1.9M
Improved glyburide therapy via acid- triggered release functional nanoparticles and therapeutic imagingR01NS110721 · NINDS · YALE UNIVERSITY · PI SHETH, KEVIN NAVIN, ZHOU, JIANGBING · 2019 to 2023
$1.9M
Yale Clinical Site: Investigations For Improved Neurological Treatments at Yale (INFINITY)U24NS107136 · NINDS · YALE UNIVERSITY · PI SHETH, KEVIN NAVIN, SPUDICH, SERENA S · 2018 to 2022
$1.7M
Yale site for Stroke Preclinical Assessment Network (SPAN) for Acute NeuroprotectionU01NS113445 · NINDS · YALE UNIVERSITY · PI SANSING, LAUREN H · 2019 to 2021
$1.2M
Anticoagulation in Intracerebral Hemorrhage Survivors with Atrial Fibrillation and Imaging Features of Cerebral Amyloid Angiopathy and Small Vessel DiseaseR01NS140459 · NINDS · YALE UNIVERSITY · PI Guido Jose Falcone, Santosh Bhaskar Murthy · 2025 to 2026
$1.1M
NIA NIH HHS P30 AG021342NIA NIH HHS T32 AG019134NINDS NIH HHS K23 NS105924NINDS NIH HHS R01 NS075209NINDS NIH HHS R01 NS110721NINDS NIH HHS R01 NS130189NINDS NIH HHS R01 NS140459NINDS NIH HHS R03 NS112859NINDS NIH HHS RF1 NS139183NINDS NIH HHS U01 NS106513NINDS NIH HHS U01 NS113445NINDS NIH HHS U24 NS107136NINDS NIH HHS U24 NS107215NINDS NIH HHS UG3 NS130228
6 · The paper itself

Abstract

White matter hyperintensities (WMH) are a common brain MRI marker of cerebral small vessel disease and a major risk factor for stroke and dementia, yet the molecular mechanisms governing lesion formation remain incompletely understood. Here, we combined large-scale proteomic and genomic data with tissue- and single-nucleus transcriptomic validation to identify circulating proteins that influence WMH volume and its downstream clinical manifestations. Association and Mendelian Randomization analyses of WMH volume and 2,923 plasma proteins in 52,560 UK Biobank participants identified the lysosomal protease cathepsin B (CTSB) and the mitochondrial enzyme Enoyl-CoA Hydratase Domain Containing 3 (ECHDC3) as the top candidates associated with WMH volume. Single-nucleus RNA sequencing of post-mortem periventricular white matter from 8 individuals (4 with WMH lesions and 4 matched controls) revealed a marked downregulation of CTSB in WMH lesions, predominantly in astrocytes and oligodendrocytes, whereas ECHDC3 expression was unchanged between cases and controls. In the UK Biobank, higher plasma CTSB levels and a cis-pQTL polygenic score each predicted better general cognitive ability, independent of vascular risk factors, whereas ECHDC3 showed no cognitive association. Together, these multimodal analyses across different studies point to CTSB as a lesion-suppressed, cognition-enhancing factor and a plausible therapeutic target for mitigating the effects of WMH and preserving brain health.

Identifiers

PMID42040931
PMCPMC13105117

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.